Pfizer has completed its acquisition of Trillium, an immuno-oncology company developing innovative cancer therapies. Trillium's portfolio includes biologics that are designed to enhance the ability of patients' innate immune systems to detect and destroy cancer cells. The deal is worth $2.26 billion.